Acute Ischemic Stroke Pipeline Summary

DelveInsight’s, “Acute Ischemic Stroke - Pipeline Insight, 2026” report provides comprehensive insights about 26+ companies and 26+ pipeline drugs in Acute Ischemic Stroke pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Acute Ischemic Stroke: Understanding

Acute Ischemic Stroke: Overview

Acute ischemic stroke (AIS) is a medical emergency characterized by the sudden loss of blood flow to a region of the brain due to arterial occlusion, resulting in focal neurological deficits. It is the most common type of stroke and a leading cause of long-term disability and mortality worldwide, requiring rapid diagnosis and treatment to minimize irreversible brain injury. AIS is primarily caused by thrombotic or embolic occlusion of cerebral arteries. Major etiologies include large artery atherosclerosis, cardioembolism (particularly due to atrial fibrillation), small vessel disease, and less commonly arterial dissection or other vascular disorders. Key risk factors include hypertension, diabetes, dyslipidemia, smoking, obesity, and advanced age.

AIS occurs when an obstruction in a cerebral artery interrupts blood flow, depriving brain tissue of oxygen and glucose. The resulting energy failure leads to depletion of adenosine triphosphate (ATP), causing loss of ion homeostasis, membrane depolarization, and excessive release of excitatory neurotransmitters such as glutamate. This initiates an ischemic cascade characterized by calcium overload, oxidative stress, mitochondrial dysfunction, inflammation, blood–brain barrier disruption, and ultimately neuronal apoptosis and necrosis. The central ischemic core sustains irreversible damage within minutes, whereas the surrounding ischemic penumbra remains metabolically impaired but viable for a limited period. Rapid reperfusion through timely therapeutic intervention can salvage the penumbra, limit infarct expansion, and improve neurological outcomes.

Diagnosis is based on rapid clinical assessment and neurological examination, followed by urgent brain imaging. Non-contrast computed tomography (CT) is the initial imaging modality used to exclude hemorrhage, while MRI, CT angiography, or MR angiography help confirm ischemia, identify large vessel occlusion, and guide reperfusion therapy.

The primary goal of AIS treatment is rapid restoration of cerebral blood flow to preserve the ischemic penumbra. Standard treatment includes intravenous thrombolysis within the eligible time window, mechanical thrombectomy for selected patients with large vessel occlusion, antiplatelet therapy, and comprehensive supportive care with secondary prevention measures to reduce recurrent stroke risk. Optimal management also includes controlling vascular risk factors, early rehabilitation, and long-term strategies such as antihypertensive, lipid-lowering, and anticoagulant therapies (when indicated) to improve functional recovery and prevent future cerebrovascular events.

"Acute Ischemic Stroke- Pipeline Insight, 2026" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Acute Ischemic Stroke pipeline landscape is provided which includes the disease overview and Acute Ischemic Stroke treatment guidelines. The assessment part of the report embraces, in depth Acute Ischemic Stroke commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Acute Ischemic Stroke collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

• The companies and academics are working to assess challenges and seek opportunities that could influence Acute Ischemic Stroke R&D. The therapies under development are focused on novel approaches to treat/improve Acute Ischemic Stroke.

Acute Ischemic Stroke Emerging Drugs Chapters

This segment of the Acute Ischemic Stroke report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Acute Ischemic Stroke Emerging Drugs

• JX10: Corxel Pharmaceuticals

JX10 is an investigational small-molecule thrombolytic agent being developed for the treatment of acute ischemic stroke (AIS). It is designed to restore cerebral blood flow in patients presenting beyond the conventional thrombolysis window. JX10 exerts pro-thrombolytic, anti-inflammatory, and antioxidative effects by modulating plasminogen activation to promote clot dissolution while simultaneously reducing inflammation and oxidative stress associated with ischemic injury. This multimodal mechanism aims to improve reperfusion, protect brain tissue, and potentially extend the therapeutic treatment window for patients with AIS. Currently, the drug is being evaluated in the Phase II/III stage of its development for the treatment of Acute Ischemic Stroke.

• TAK-755: Takeda Pharmaceutical Company Limited

TAK-755 is a recombinant human ADAMTS13 enzyme replacement therapy being developed for acute ischemic stroke (AIS). It is designed to restore ADAMTS13 activity, which cleaves ultra-large von Willebrand factor (vWF) multimers that accumulate following endothelial injury during stroke. By reducing vWF-mediated platelet aggregation and microvascular thrombosis, TAK-755 helps improve cerebral microcirculation, limit thromboinflammation, and reduce ischemic brain damage. Unlike thrombolytic therapies that dissolve fibrin clots, TAK-755 targets the vWF–platelet pathway, offering a novel approach to preserving brain tissue and improving neurological outcomes. Currently, the drug is being evaluated in the Phase II stage of its development for the treatment of Acute Ischemic Stroke.

• RNS60: Revalesio Corporation

RNS60 is an investigational physically modified saline developed for the treatment of acute ischemic stroke (AIS). Unlike conventional pharmacological agents, RNS60 contains charge-stabilized oxygen nanobubbles that exert anti-inflammatory, neuroprotective, and immunomodulatory effects without an active pharmaceutical ingredient. It is believed to modulate cellular signaling pathways, suppress neuroinflammation, reduce oxidative stress, improve mitochondrial function, and promote neuronal survival following cerebral ischemia. Through these mechanisms, RNS60 aims to limit ischemic brain injury and enhance functional recovery after stroke. Currently, the drug is being evaluated in the Phase II stage of its development for the treatment of Acute Ischemic Stroke.

• HRS-4029: Beijing Suncadia Pharmaceuticals Co., Ltd.

HRS-4029 is an investigational neuroprotective agent being developed for the treatment of acute ischemic stroke (AIS). The therapy is designed to reduce neuronal damage caused by cerebral ischemia and improve neurological recovery when used alongside standard stroke management. Although its precise mechanism of action has not been publicly disclosed, HRS-4029 is intended to protect brain tissue by mitigating ischemia-induced cellular injury and preserving neuronal function, with the goal of improving functional outcomes in patients with AIS. Currently, the drug is being evaluated in the Phase I stage of its development for the treatment of Acute Ischemic Stroke.

Further product details are provided in the report……..

Acute Ischemic Stroke: Therapeutic Assessment

This segment of the report provides insights about the different Acute Ischemic Stroke drugs segregated based on following parameters that define the scope of the report, such as:

• Major Players in Acute Ischemic Stroke

There are approx. 26+ key companies which are developing the therapies Acute Ischemic Stroke. The companies which have their Acute Ischemic Stroke drug candidates in the most advanced stage, i.e. Phase II/III include, Corxel Pharmaceuticals and others.

• Phases

DelveInsight’s report covers around 26+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

• Route of Administration

Acute Ischemic Stroke pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Intra-articular
• Intraocular
• Intrathecal
• Intravenous
• Ophthalmic
• Oral
• Parenteral
• Subcutaneous
• Topical
• Transdermal

• Molecule Type

Products have been categorized under various Molecule types such as

• Oligonucleotide
• Peptide
• Small molecule

• Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Acute Ischemic Stroke: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Acute Ischemic Stroke therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Acute Ischemic Stroke drugs.

Acute Ischemic Stroke Report Insights

• Acute Ischemic Stroke Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Acute Ischemic Stroke Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Acute Ischemic Stroke drugs?
• How many Acute Ischemic Stroke drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Acute Ischemic Stroke?
• What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Acute Ischemic Stroke therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Acute Ischemic Stroke and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Takeda Pharmaceutical Company Limited.
• Shaanxi Micot Pharmaceutical Technology Co., Ltd.
• Shanghai QuietD Biotechnology
• Tasly Pharma Co., Ltd.
• Revalesio Corporation
• CSPC Mingfule Pharmaceutical (Guangzhou) Co., Ltd.
• Basking Biosciences
• NoNO Inc.
• Corxel Pharmaceuticals
• Beijing Suncadia Pharmaceuticals Co., Ltd.

Key Products

• TAK-755
• MT200605
• QD202
• B2065
• RNS60
• rhTNK-tPA
• BB-031
• NoNO-42
• JX10
• HRS-4029